- Home
- Publications
- Publication Search
- Publication Details
Title
Orphan drug policies and use in pediatric nephrology
Authors
Keywords
Orphan drug, Rare disease, Quality-adjusted life-year, Fabry disease, Atypical hemolytic uremic syndrome, Cystinosis
Journal
PEDIATRIC NEPHROLOGY
Volume 32, Issue 1, Pages 1-6
Publisher
Springer Nature
Online
2016-10-13
DOI
10.1007/s00467-016-3520-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Controversies and research agenda in nephropathic cystinosis: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
- (2016) Craig B. Langman et al. KIDNEY INTERNATIONAL
- Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
- (2016) Larry A. Greenbaum et al. KIDNEY INTERNATIONAL
- The management and treatment of children with Fabry disease: A United States-based perspective
- (2016) Robert J. Hopkin et al. MOLECULAR GENETICS AND METABOLISM
- Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks
- (2016) Carla E. M. Hollak et al. Orphanet Journal of Rare Diseases
- Rare diseases and effective treatments: are we delivering?
- (2015) Lucio Luzzatto et al. LANCET
- An international consensus approach to the management of atypical hemolytic uremic syndrome in children
- (2015) Chantal Loirat et al. PEDIATRIC NEPHROLOGY
- Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
- (2015) Todd Gammie et al. PLoS One
- Pricing for Orphan Drugs
- (2013) Brian P. O’Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
- (2013) C.M. Legendre et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on White Blood Cell Cystine Levels and Comparison of Safety
- (2012) C. B. Langman et al. Clinical Journal of the American Society of Nephrology
- What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis
- (2012) C. Thorat et al. PEDIATRICS
- Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults
- (2011) Albane Brodin-Sartorius et al. KIDNEY INTERNATIONAL
- A comparative study of European rare disease and orphan drug markets
- (2010) Alain Denis et al. HEALTH POLICY
- Priority setting for orphan drugs: An international comparison
- (2010) Zahava R.S. Rosenberg-Yunger et al. HEALTH POLICY
- Therapies for Inborn Errors of Metabolism: What Has the Orphan Drug Act Delivered?
- (2010) S. S. Talele et al. PEDIATRICS
- Availability of and Access to Orphan Drugs
- (2010) Carl Rudolf Blankart et al. PHARMACOECONOMICS
- Translation of rare disease research into orphan drug development: disease matters
- (2009) Harald E. Heemstra et al. DRUG DISCOVERY TODAY
- International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?
- (2009) Takeru Shiroiwa et al. HEALTH ECONOMICS
- The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
- (2009) Olivier Wellman-Labadie et al. HEALTH POLICY
- Does orphan drug legislation really answer the needs of patients?
- (2008) Marlene E Haffner et al. LANCET
- Empowerment of patients: lessons from the rare diseases community
- (2008) Ségolène Aymé et al. LANCET
- Why rare diseases are an important medical and social issue
- (2008) Arrigo Schieppati et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started